Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Intensive Care Medicine
Erschienen in: Intensive Care Medicine 10/2018

11.09.2018 | Review

Conflicts of interest in infection prevention and control research: no smoke without fire. A narrative review

verfasst von: Mohamed Abbas, Daniela Pires, Alexandra Peters, Chantal M Morel, Samia Hurst, Alison Holmes, Hiroki Saito, Benedetta Allegranzi, Jean-Christophe Lucet, Walter Zingg, Stephan Harbarth, Didier Pittet

Erschienen in: Intensive Care Medicine | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Conflicts of interest (COIs) do occur in healthcare research, yet their impact on research in the field of infection prevention and control (IPC) is unknown. We conducted a narrative review aiming to identify examples of COIs in IPC research. In addition to well-known instances, we conducted PubMed and Google searches to identify and report case studies of COIs in IPC and antimicrobial resistance (AMR), which were chosen arbitrarily following consensus meetings, to illustrate different types of COIs. We also searched the Retraction Watch database and blog to systematically identify retracted IPC and/or infectious disease-related papers. Our review highlights COIs in academic research linked to ties between industry and physicians, journal editors, peer-reviewed journals' choice for publication, and guideline committees participants and authors. It explores how COIs can affect research and could be managed. We also present several selected case studies that involve (1) the chlorhexidine industry and how it has used marketing trials and key opinion leaders to promote off-label use of its products; (2) the copper industry and how reporting of its trials in IPC have furthered their agenda; (3) the influence of a company developing “closed infusion systems” for catheters and how this affects networks in low- and middle-income countries and guideline development; (4) potential perverse incentives hospitals may have in reporting healthcare-associated infection or AMR rates and how government intervention may restrict AMR research for fear of bad publicity and subsequent negative economic consequences. Finally, the analysis of reasons for the retraction of previously published papers highlights the fact that misconduct in research may have other motivations than financial gain, the most visible form of COIs. COIs occur in the field of research in general, and IPC and AMR are no exceptions. Their effects pervade all aspects of the research and publication processes. We believe that, in addition to improvements in management strategies of COIs, increased public funding should be available to decrease researchers’ dependency on industry ties. Further research is needed on COIs and their management.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Thompson DF (1993) Understanding financial conflicts of interest. N Engl J Med 329(8):573–576PubMed
2.
Goodman S, Dickersin K (2011) Metabias: a challenge for comparative effectiveness research. Ann Intern Med 155(1):61–62PubMed
3.
Wiersma M, Kerridge I, Lipworth W (2018) Dangers of neglecting non-financial conflicts of interest in health and medicine. J Med Ethics 44(5):319–322PubMed
4.
Luty J, Arokiadass SM, Easow JM, Anapreddy JR (2009) Preferential publication of editorial board members in medical specialty journals. J Med Ethics 35(3):200–202PubMed
5.
Abdoul H, Perrey C, Tubach F, Amiel P, Durand-Zaleski I, Alberti C (2012) Non-financial conflicts of interest in academic grant evaluation: a qualitative study of multiple stakeholders in France. PLoS One 7(4):e35247PubMedPubMedCentral
6.
Partnerships for Children and Health (2017) In: Andonova LB (ed) Governance entrepreneurs: international organizations and the rise of global public-private partnerships. Business and public policy. Cambridge University Press, Cambridge, pp 145–192
7.
Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA (2017) Types and distribution of payments from industry to physicians in 2015. JAMA 317(17):1774–1784PubMedPubMedCentral
8.
9.
Liu JJ, Bell CM, Matelski JJ, Detsky AS, Cram P (2017) Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study. BMJ (Clin Res Ed) 359:j4619
10.
Lundh A, Barbateskovic M, Hrobjartsson A, Gotzsche PC (2010) Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue—cohort study. PLoS Med 7(10):e1000354PubMedPubMedCentral
11.
International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals. http://​www.​icmje.​org/​. Accessed 24 May 2018
12.
Matheson A (2016) The ICMJE Recommendations and pharmaceutical marketing–strengths, weaknesses and the unsolved problem of attribution in publication ethics. BMC Med Ethics. 17:20PubMedPubMedCentral
13.
Loder E, Brizzell C, Godlee F (2015) Revisiting the commercial-academic interface in medical journals. BMJ (Clin Res Ed) 350:h2957
14.
15.
Andreatos N, Zacharioudakis IM, Zervou FN, Muhammed M, Mylonakis E (2017) Discrepancy between financial disclosures of authors of clinical practice guidelines and reports by industry. Med (Baltim) 96(2):e5711
16.
Morciano C, Basevi V, Faralli C, Hilton Boon M, Tonon S, Taruscio D (2016) Policies on conflicts of interest in health care guideline development: a cross-sectional analysis. PLoS One 11(11):e0166485PubMedPubMedCentral
17.
Edmond M, Eickhoff TC (2008) Who is steering the ship? External influences on infection control programs. Clin Infect Dis 46(11):1746–1750PubMed
18.
Campbell EG, Weissman JS, Ehringhaus S, Rao SR, Moy B, Feibelmann S et al (2007) Institutional academic industry relationships. JAMA 298(15):1779–1786PubMed
19.
Angell M (2000) Is academic medicine for sale? N Engl J Med 342(20):1516–1518PubMed
20.
21.
Resnik DB, Ariansen JL, Jamal J, Kissling GE (2016) Institutional conflict of interest policies at US. Academic research institutions. Acad Med 91(2):242–246PubMedPubMedCentral
22.
Scheffer P, Guy-Coichard C, Outh-Gauer D, Calet-Froissart Z, Boursier M, Mintzes B et al (2017) Conflict of interest policies at French medical schools: starting from the bottom. PLoS One 12(1):e0168258PubMedPubMedCentral
23.
Grande D, Frosch DL, Perkins AW, Kahn BE (2009) Effect of exposure to small pharmaceutical promotional items on treatment preferences. Arch Intern Med 169(9):887–893PubMed
24.
Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S et al (2017) Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 317(17):1785–1795PubMedPubMedCentral
25.
Epstein AJ, Busch SH, Busch AB, Asch DA, Barry CL (2013) Does exposure to conflict of interest policies in psychiatry residency affect antidepressant prescribing? Med Care 51(2):199–203PubMed
26.
King M, Essick C, Bearman P, Ross JS (2013) Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis. BMJ (Clin Res Ed) 346:f264
27.
Beyhun NE, Kolayli CC, Can G, Topbas M (2016) Turkish final year medical students’ exposure to and attitudes concerning drug company interactions: a perspective from a minimally regulated environment for medical students. PLoS One 11(12):e0168094PubMedPubMedCentral
28.
Filippiadou M, Kouvelas D, Garyfallos G, Tsakiridis I, Tzachanis D, Spachos D et al (2017) Exposure to the drug company marketing in Greece: interactions and attitudes in a non-regulated environment for medical students. Ann Med Surg 19:23–28
29.
Jahnke K, Kremer MS, Schmidt CO, Kochen MM, Chenot JF (2014) German medical students’ exposure and attitudes toward pharmaceutical promotion: a cross-sectional survey. GMS Zeitschrift fur Medizinische Ausbildung 31(3):Doc32PubMedPubMedCentral
30.
Austad KE, Avorn J, Kesselheim AS (2011) Medical students’ exposure to and attitudes about the pharmaceutical industry: a systematic review. PLoS Med 8(5):e1001037PubMedPubMedCentral
31.
Bekelman JE, Li Y, Gross CP (2003) Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289(4):454–465PubMed
32.
Saito H, Gill CJ (2014) How frequently do the results from completed US clinical trials enter the public domain?–A statistical analysis of the ClinicalTrials.gov database. PLoS One 9(7):e101826PubMedPubMedCentral
33.
Jones CW, Handler L, Crowell KE, Keil LG, Weaver MA, Platts-Mills TF (2013) Non-publication of large randomized clinical trials: cross sectional analysis. BMJ (Clin Res Ed) 347:f6104
34.
Bassler D, Mueller KF, Briel M, Kleijnen J, Marusic A, Wager E et al (2016) Bias in dissemination of clinical research findings: structured OPEN framework of what, who and why, based on literature review and expert consensus. BMJ Open 6(1):e010024PubMedPubMedCentral
35.
Evoniuk G, Mansi B, DeCastro B, Sykes J (2017) Impact of study outcome on submission and acceptance metrics for peer reviewed medical journals: 6 year retrospective review of all completed GlaxoSmithKline human drug research studies. BMJ (Clin Res Ed) 357:j1726
36.
Spiegel R, Opic P, Semmlack S, Tschudin-Sutter S, Sutter R (2017) Tackling submission and publication bias. BMJ (Clin Res Ed) 358:j3436
37.
Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L (2017) Industry sponsorship and research outcome. Cochrane Database Syst Rev 2:MR000033PubMed
38.
Boutron I, Dutton S, Ravaud P, Altman DG (2010) Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303(20):2058–2064PubMed
39.
Boutron I, Altman DG, Hopewell S, Vera-Badillo F, Tannock I, Ravaud P (2014) Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial. J Clin Oncol 32(36):4120–4126PubMed
40.
Yavchitz A, Boutron I, Bafeta A, Marroun I, Charles P, Mantz J et al (2012) Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study. PLoS Med 9(9):e1001308PubMedPubMedCentral
41.
Kaestner V, Brown A, Tao D, Prasad V (2017) Conflicts of interest in twitter. Lancet Haematol 4(9):e408–e409PubMed
42.
Tao DL, Boothby A, McLouth J, Prasad V (2017) Financial conflicts of interest among hematologist-oncologists on twitter. JAMA Intern Med 177(3):425–427PubMed
43.
Huttner A, Kaiser L (2017) Fair reporting of study results. Clin Microbiol Infect 23(6):345–346PubMed
44.
World Medical A (2013) World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191–2194
45.
Jacmon H (2018) Disclosure is inadequate as a solution to managing conflicts of interest in human research. J Bioeth Inq 15(1):71–80PubMed
46.
Hurst SA, Mauron A (2008) A question of method. The ethics of managing conflicts of interest. EMBO Rep 9(2):119–123PubMedPubMedCentral
47.
World Health Organization (2014) WHO handbook for guideline development, 2nd edn. World Health Organization, Geneva
48.
49.
50.
Vernon MO, Hayden MK, Trick WE, Hayes RA, Blom DW, Weinstein RA et al (2006) Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 166(3):306–312PubMed
51.
Bleasdale SC, Trick WE, Gonzalez IM, Lyles RD, Hayden MK, Weinstein RA (2007) Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 167(19):2073–2079PubMed
52.
Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA et al (2013) Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 368(6):533–542PubMedPubMedCentral
53.
Munoz-Price LS, Hota B, Stemer A, Weinstein RA (2009) Prevention of bloodstream infections by use of daily chlorhexidine baths for patients at a long-term acute care hospital. Infect Control Hosp Epidemiol 30(11):1031–1035PubMed
54.
Popovich KJ, Hota B, Hayes R, Weinstein RA, Hayden MK (2009) Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit. Infect Control Hosp Epidemiol 30(10):959–963PubMed
55.
Popovich KJ, Hota B, Hayes R, Weinstein RA, Hayden MK (2010) Daily skin cleansing with chlorhexidine did not reduce the rate of central-line associated bloodstream infection in a surgical intensive care unit. Intensive Care Med 36(5):854–858PubMed
56.
Noto MJ, Domenico HJ, Byrne DW, Talbot T, Rice TW, Bernard GR et al (2015) Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. JAMA 313(4):369–378PubMedPubMedCentral
57.
Afonso E, Blot K, Blot S (2016) Prevention of hospital-acquired bloodstream infections through chlorhexidine gluconate-impregnated washcloth bathing in intensive care units: a systematic review and meta-analysis of randomised crossover trials. Euro Surveill 21(46):30400PubMedCentral
58.
Frost SA, Alogso MC, Metcalfe L, Lynch JM, Hunt L, Sanghavi R et al (2016) Chlorhexidine bathing and health care-associated infections among adult intensive care patients: a systematic review and meta-analysis. Crit Care 20(1):379 (London, England) PubMedPubMedCentral
59.
Shirahatti RG, Joshi RM, Vishwanath YK, Shinkre N, Rao S, Sankpal JS et al (1993) Effect of pre-operative skin preparation on post-operative wound infection. J Postgrad Med 39(3):134–136PubMed
60.
Weiner LM, Webb AK, Walters MS, Dudeck MA, Kallen AJ (2016) Policies for controlling multidrug-resistant organisms in US healthcare facilities reporting to the national healthcare safety network, 2014. Infect Control Hosp Epidemiol 37(9):1105–1108PubMedPubMedCentral
61.
62.
Harbarth S, Tuan Soh S, Horner C, Wilcox MH (2014) Is reduced susceptibility to disinfectants and antiseptics a risk in healthcare settings? A point/counterpoint review. J Hosp Infect 87(4):194–202PubMed
63.
Kampf G (2016) Acquired resistance to chlorhexidine—is it time to establish an ‘antiseptic stewardship’ initiative? J Hosp Infect 94(3):213–227PubMed
64.
Beattie AH, Prach AT, Baxter JP, Pennington CR (2000) A randomised controlled trial evaluating the use of enteral nutritional supplements postoperatively in malnourished surgical patients. Gut 46(6):813–818PubMedPubMedCentral
65.
Wu AW, Kavanagh KT, Pronovost PJ, Bates DW (2014) Conflict of interest, Dr Charles Denham and the journal of patient safety. J Patient Saf 10(4):181–185PubMed
66.
67.
68.
Weber DJ, Otter JA, Rutala WA (2017) Can copper-coated surfaces prevent healthcare-associated infections? Infect Control Hosp Epidemiol 38(7):772–776PubMed
69.
Salgado CD, Sepkowitz KA, John JF, Cantey JR, Attaway HH, Freeman KD et al (2013) Copper surfaces reduce the rate of healthcare-acquired infections in the intensive care unit. Infect Control Hosp Epidemiol 34(5):479–486PubMed
70.
Harbarth S, Maiwald M, Dancer SJ (2013) The environment and healthcare-acquired infections: why accurate reporting and evaluation of biological plausibility are important. Infect Control Hosp Epidemiol 34(9):996–997PubMed
71.
Souli M, Antoniadou A, Katsarolis I, Mavrou I, Paramythiotou E, Papadomichelakis E et al (2017) Reduction of environmental contamination with multidrug-resistant bacteria by copper-alloy coating of surfaces in a highly endemic setting. Infect Control Hosp Epidemiol 38(7):765–771PubMed
72.
von Dessauer B, Navarrete MS, Benadof D, Benavente C, Schmidt MG (2016) Potential effectiveness of copper surfaces in reducing health care-associated infection rates in a pediatric intensive and intermediate care unit: a nonrandomized controlled trial. Am J Infect Control 44(8):e133–e139
73.
Muller MP, MacDougall C, Lim M, Ontario Agency for Health P, Promotion Public Health O, Provincial Infectious Diseases Advisory Committee on Infection P et al (2016) Antimicrobial surfaces to prevent healthcare-associated infections: a systematic review. J Hosp Infect 92(1):7–13PubMed
74.
Schmidt MG, Salgado CD, Freeman KD, John JF, Cantey JR, Sharpe PA et al (2018) Antimicrobial surfaces to prevent healthcare-associated infections: a systematic review—a different view. J Hosp Infect 99(3):309–311PubMed
75.
76.
77.
Rosenthal VD, Maki DG, Graves N (2008) The International Nosocomial Infection Control Consortium (INICC): goals and objectives, description of surveillance methods, and operational activities. Am J Infect Control 36(9):e1–e12PubMed
78.
Rosenthal VD (2016) International Nosocomial Infection Control Consortium (INICC) resources: INICC multidimensional approach and INICC surveillance online system. Am J Infect Control 44(6):e81–e90PubMed
79.
Rosenthal VD, Guzman S, Crnich C (2004) Device-associated nosocomial infection rates in intensive care units of Argentina. Infect Control Hosp Epidemiol 25(3):251–255PubMed
80.
Rangel-Frausto MS, Higuera-Ramirez F, Martinez-Soto J, Rosenthal VD (2010) Should we use closed or open infusion containers for prevention of bloodstream infections? Ann Clin Microbiol Antimicrob 9:6PubMedPubMedCentral
81.
Vilins M, Blecher S, Silva MA, Rosenthal VD, Barker K, Salomao R (2009) Rate and time to develop first central line-associated bloodstream infections when comparing open and closed infusion containers in a Brazilian Hospital. Braz J Infect Dis 13(5):335–340PubMed
82.
Franzetti F, Borghi B, Raimondi F, Rosenthal VD (2009) Impact on rates and time to first central vascular-associated bloodstream infection when switching from open to closed intravenous infusion containers in a hospital setting. Epidemiol Infect 137(7):1041–1048PubMed
83.
Maki DG, Rosenthal VD, Salomao R, Franzetti F, Rangel-Frausto MS (2011) Impact of switching from an open to a closed infusion system on rates of central line-associated bloodstream infection: a meta-analysis of time-sequence cohort studies in 4 countries. Infect Control Hosp Epidemiol 32(1):50–58PubMed
84.
Graves N, Barnett AG, Rosenthal VD (2011) Open versus closed IV infusion systems: a state based model to predict risk of catheter associated blood stream infections. BMJ Open 1(2):e000188PubMedPubMedCentral
85.
Mainous MR, Deitch EA (1994) Nutrition and infection. Surg Clin North Am 74(3):659–676PubMed
86.
Mazaki T, Ishii Y, Murai I (2015) Immunoenhancing enteral and parenteral nutrition for gastrointestinal surgery: a multiple-treatments meta-analysis. Ann Surg 261(4):662–669PubMed
87.
Haustein T, Gastmeier P, Holmes A, Lucet JC, Shannon RP, Pittet D et al (2011) Use of benchmarking and public reporting for infection control in four high-income countries. Lancet Infect Dis 11(6):471–481PubMed
88.
Masnick M, Morgan DJ, Sorkin JD, Kim E, Brown JP, Rheingans P et al (2016) Lack of patient understanding of hospital-acquired infection data published on the centers for medicare and medicaid services hospital compare website. Infect Control Hosp Epidemiol 37(2):182–187PubMed
89.
Mitchell BG, Shaban RZ, MacBeth D, Wood CJ, Russo PL (2017) The burden of healthcare-associated infection in Australian hospitals: a systematic review of the literature. Infect Dis Health 22(3):117–128PubMed
90.
Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H, Donaldson L et al (2011) Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet 377(9761):228–241 (London, England) PubMed
91.
Lee GM, Kleinman K, Soumerai SB, Tse A, Cole D, Fridkin SK et al (2012) Effect of nonpayment for preventable infections in US hospitals. N Engl J Med 367(15):1428–1437PubMed
92.
Ashley EA, Recht J, Chua A, Dance D, Dhorda M, Thomas NV et al (2018) An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000. J Antimicrob Chemother 73(7):1737–1749PubMedPubMedCentral
93.
Monnet DL (2000) Toward multinational antimicrobial resistance surveillance systems in Europe. Int J Antimicrob Agents 15(2):91–101PubMed
94.
Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A et al (2018) Surveillance for control of antimicrobial resistance. Lancet Infect Dis 18(3):e99–e106PubMed
95.
World Health Organization (2018) Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2016–2017. World Health Organization, Geneva
96.
Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R et al (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10(9):597–602PubMedPubMedCentral
97.
European Centre for Disease Prevention and Control (2011) Updated risk assessment on the spread of NDM and its variants within Europe. ECDC, Stockholm
98.
Pesesky MW, Hussain T, Wallace M, Wang B, Andleeb S, Burnham CA et al (2015) KPC and NDM-1 genes in related enterobacteriaceae strains and plasmids from Pakistan and the United States. Emerg Infect Dis 21(6):1034–1037PubMedPubMedCentral
99.
Chen D, Gong L, Walsh TR, Lan R, Wang T, Zhang J et al (2016) Infection by and dissemination of NDM-5-producing Escherichia coli in China. J Antimicrob Chemother 71(2):563–565PubMed
100.
Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K et al (2009) Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53(12):5046–5054PubMedPubMedCentral
101.
Walsh TR, Weeks J, Livermore DM, Toleman MA (2011) Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 11(5):355–362PubMed
102.
103.
104.
Derde LP, Dautzenberg MJ, Bonten MJ (2012) Chlorhexidine body washing to control antimicrobial-resistant bacteria in intensive care units: a systematic review. Intensive Care Med 38(6):931–939PubMedPubMedCentral
105.
Bretagnol F, Panis Y, Rullier E, Rouanet P, Berdah S, Dousset B et al (2010) Rectal cancer surgery with or without bowel preparation: the French GRECCAR III multicenter single-blinded randomized trial. Ann Surg 252(5):863–868PubMed
106.
Steen RG, Casadevall A, Fang FC (2013) Why has the number of scientific retractions increased? PLoS One 8(7):e68397PubMedPubMedCentral
107.
Saver RS (2012) Is it really all about the money? Reconsidering non-financial interests in medical research. J Law Med Eth 40(3):467–481
108.
Wiersma M, Kerridge I, Lipworth W, Rodwin M (2018) Should we try to manage non-financial interests? BMJ (Clin Res Ed) 361:k1240
109.
110.
Metadaten
Titel
Conflicts of interest in infection prevention and control research: no smoke without fire. A narrative review
verfasst von
Mohamed Abbas
Daniela Pires
Alexandra Peters
Chantal M Morel
Samia Hurst
Alison Holmes
Hiroki Saito
Benedetta Allegranzi
Jean-Christophe Lucet
Walter Zingg
Stephan Harbarth
Didier Pittet
Publikationsdatum
11.09.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 10/2018
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-018-5361-z

Weitere Artikel der Ausgabe 10/2018

Intensive Care Medicine 10/2018 Zur Ausgabe

Original

Mortality attributable to different Klebsiella susceptibility patterns and to the coverage of empirical antibiotic therapy: a cohort study on patients admitted to the ICU with infection

Imaging in Intensive Care Medicine

Pulsatile bleeding after sternal bone marrow puncture

Editorial

Do I have a conflict of interest? Yes

What's New in Intensive Care

Declaration of conflicts of interest: a ‘crooked’ line towards scientific integrity

What's New in Intensive Care

The Boldt scandal still in need of action: the example of colloids 10 years after initial suspicion of fraud

Systematic Review

Association of conflicts of interest with the results and conclusions of goal-directed hemodynamic therapy research: a systematic review with meta-analysis

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung
weitere anzeigen

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren